Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders

(2014) Tamima Ashraf et al.   CURRENT PHARMACEUTICAL DESIGN

The phenolic metabolites of the anti-HIV drug efavirenz: Evidence for distinct reactivities upon oxidation with Frémy's salt

(2014) Shrika G. Harjivan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy

(2014) B. Mora-Peris et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

(2014)   LANCET

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

(2013) Matteo Vassallo et al.   AIDS

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients

(2013) F. S. Sarfo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

8-Hydroxy-efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes

(2013) Maria Brandmann et al.   NEUROCHEMICAL RESEARCH

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

(2012) Alexia Cusini et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting

(2012) Timothy Rawson et al.   JOURNAL OF INFECTION

Antiretroviral neurotoxicity

(2012) Kevin Robertson et al.   JOURNAL OF NEUROVIROLOGY

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

(2011) N. Ciccarelli et al.   NEUROLOGY

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

(2010) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

(2010) E. T. Ogburn et al.   DRUG METABOLISM AND DISPOSITION

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

(2010) B. M. Best et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY